Introduction
============

Traumatic brain injury (TBI) is a leading cause of death and disability worldwide, particularly amongst young adults. Ten million individuals are affected by TBI annually, costing a staggering \$9--10 billion/year ([@B33]). The aged population have a greater risk of sustaining a TBI, with frequent falls being the major cause of injury, and they also have worse outcomes post-injury compared to other age groups ([@B99]). Aging is also accompanied by a number of co-morbidities which may contribute to poorer outcomes in these individuals following TBI ([@B99]). Common secondary events that follow the primary impact are neuronal cell death, oxidative stress, brain oedema, blood-brain barrier (BBB) breakdown, and inflammation ([@B101]). TBI often results in debilitating long-term cognitive and motor impairments, and there are currently no approved treatments available for TBI patients ([@B16]). This highlights the need for therapeutic agents that can alleviate brain damage and the deficits caused by the primary injury and more specifically the reversible secondary pathologies that develop after TBI.

Iron homeostasis appears to be an important process in the pathobiology of TBI. Iron is essential for normal brain functioning where it acts as an essential cofactor for several enzymatic/cellular processes ([@B55]). However, impaired regulation of iron can result in the production of reactive oxygen species (ROS) and the consequent promotion of oxidative stress, which can wreak havoc on an already compromised brain in the context of TBI ([@B77]). Interestingly, the accumulation of iron in various tissues and cells in the body and brain is an inevitable consequence of aging ([@B40]; [@B23]). A concomitant increase in the iron storage protein (i.e., ferritin), which can scavenge any excess iron and prevent undesired production of ROS, is also evident with aging ([@B3]). However, failed or weakened antioxidant defenses and mitochondrial dysfunction that progresses with aging can disrupt the balance and allow for excessive iron to be released ([@B108],[@B109]; [@B3]). This can cause pathological iron overload resulting in cellular damage that is considered to be a contributing factor in several degenerative diseases that are more prevalent with age, such as cancer, liver fibrosis, cardiovascular disease, diabetes (type II), and particularly neurological conditions such as Alzheimer's disease (AD) ([@B95]; [@B54]; [@B111]; [@B44]). Abnormal brain iron deposition has also been discovered in other neurodegenerative diseases, such as Parkinson's disease (PD) ([@B37]; [@B124]; [@B11]), multiple sclerosis (MS) ([@B12]), amyotrophic lateral sclerosis (ALS) ([@B80]), Huntington's disease ([@B2]), and Friedreich's ataxia ([@B72]), and there is now increasing evidence of altered iron levels in TBI patients ([@B88]; [@B70]). This raises the interesting proposition of an intersection between aging, iron, TBI and neurodegenerative disease. Whilst the role of iron in TBI is not well known, the literature suggests that the levels of iron (and other metals such as zinc) are abnormally regulated following injury, and that the pharmacological targeting (e.g., using chelators or chaperones) of these metals may be beneficial in improving outcomes. Iron chelation therapy has been approved for decades for the treatment of iron overload conditions, and there is a recent heightened interest for their use in neurodegenerative diseases ([@B54]; [@B28]). Here, we review the role of iron dyshomeostasis in TBI and gain a deeper understanding of its involvement in neurodegeneration as well as neuroinflammation (Figure [1](#F1){ref-type="fig"}). We further examine the potential benefit of utilizing iron chelation therapy with the hope of limiting iron-induced neurotoxicity in TBI.

![The consequence of iron dyshomeostasis following TBI. TBI results in several secondary events including blood-brain barrier (BBB) breakdown, hemorrhage and iron dyshomeostasis. Together this leads to the accumulation of heme and/or non-heme bound iron in the brain. Iron can participate in Haber-Weiss/Fenton reactions and can promote oxidative stress, neuronal death, inflammation as well as tau phosphorylation/amyloid-β deposition. This contributes to the pathology of TBI, ultimately resulting in neurological decline and an increased risk of developing neurodegenerative disease.](fnins-12-00981-g001){#F1}

Iron Homeostasis and Its Role in Neurological Function
======================================================

Iron is an important cofactor involved in a variety of bodily functions including cellular metabolism, energy production, cell growth and differentiation, and gene expression. It is primarily recognized for its ability to bind oxygen, contained within the hemoglobin complex, to transport oxygen throughout the body ([@B82]). Iron is also, however, fundamental for neuronal development, synaptic plasticity, neurotransmitter processing, and myelination ([@B55]; [@B111]). In the brain, iron, as well as other biometals, are found in numerous cell types including neurons, astrocytes, microglia, and most abundantly in oligodendrocytes ([@B17]; [@B4]). Astrocytes that are an integral part of the BBB have the ability to take up circulating iron and redistribute it to other cells in the CNS ([@B27]). Iron is crucial for the maintenance of myelin, and therefore oligodendrocytes require a constant supply of iron ([@B21]). Iron is also essential for optimal mitochondrial function ([@B104]), which is critical for neurons and other brain residing cells that have significant energy and metabolic requirements.

Iron homeostasis is carefully regulated in mammals by a plethora of proteins and enzymes produced in the liver such as hepcidin and ceruloplasmin, and other iron transporters (divalent metal transporter 1: DMT1, ferroportin, and transferrin) and their receptors ([@B55]). The expression levels of these proteins/receptors are in turn regulated by iron responsive elements (IRE) and iron regulatory proteins (IRP) especially when iron levels are low ([@B102]). Iron generally exists in an insoluble ferric (Fe^3+^) or soluble ferrous (Fe^2+^) state and is an active participant in electron transfer/redox reactions, which can drive oxidative stress-induced cellular toxicity ([@B36]; [@B77]). Iron is solely absorbed through the diet, usually in its ferric form, and needs to be reduced to Fe^2+^ for its essential cellular uptake via transporter DMT1, with ferrous iron also released from cells via ferroportin ([@B38]; [@B25]). In the circulation, iron is transported by binding to transferrin (ferric state; 2:1 ratio) whereas in tissues it is stored in a stable conformation by ferritin, a protein that consists of two subunits (i.e., ferritin heavy chain and light chain) ([@B55]; [@B77]; [@B111]). The main regulator and inhibitor of iron release is hepcidin, which is secreted by the liver in response to stimulants (e.g., human hemochromatosis protein (HFE), inflammatory mediator IL-6, lipopolysaccharides (LPS) or high transferrin-Fe^3+^ complexes) ultimately to reduce levels of iron in the body ([@B32]; [@B111]).

The Metabolism of Iron in the Brain
===================================

The entry of iron into the brain parenchyma is restricted by the BBB due to its hydrophilic nature. Iron (ferric iron: Fe^3+^) can enter through endothelial cells that line the BBB typically via endocytosis of transferrin/transferrin receptors and to a lesser extent either independently (non-transferrin bound iron) or as a low molecular weight complex ([@B55]; [@B102]; [@B111]). Iron is released from transferrin due to the acidic pH environment of the endosome, is then reduced to ferrous iron and thus contributes to the labile ferrous iron pool ([@B55]). Ferroportin is the only known iron exporter for almost all cell types including neurons and astrocytes ([@B25]). Ceruloplasmin, which is primarily a copper containing α2-globulin (binds six copper ions) and mainly present as a GPI-linked membrane protein in the brain, is also an important regulator of iron-mediated transport via binding ferroportin and driving the conversion of Fe^2+^ to Fe^3+^ by its ferroxidase activity ([@B5]). Amyloid precursor protein (APP), a key protein in AD pathology, stabilizes ferroportin to facilitate iron export in neurons, and its activity has recently been found to be regulated by iron ([@B89]; [@B115]). Ceruloplasmin and APP expression are both increased alongside iron accumulation in the brain of TBI patients and brain injured mice, and were found to elicit neuroprotective effects ([@B10]). Figure [2](#F2){ref-type="fig"} summarizes the proteins/receptors involved in iron metabolism in the brain.

![Iron metabolism in the healthy and traumatically injured brain. **(A)** Circulating iron (Fe^3+^) passes the blood-brain barrier (BBB) either bound to transferrin or independently, and is then taken up by endothelial cells expressing transferrin receptors via endocytosis. The acidic pH environment of the endosome detaches Fe^3+^ from transferrin and Fe^3+^ is then reduced to Fe^2+^ by ferric reductase ([@B111]). In the brain, Fe^2+^ is uptaken via DMT1 and distributed amongst astrocytes, neurons, oligodendrocytes, and microglia. Inside these cells, Fe^2+^ is converted to Fe^3+^ and stored by ferritin to prevent oxidative damage ([@B80]). Oligodendrocytes express Tim2 receptor that binds ferritin and iron can be imported through this mechanism, in addition to DMT1. Neurons and microglia can also uptake transferrin-bound iron via transferrin receptors ([@B111]). Ferrous iron is exported from cells via the iron exporter, ferroportin, which is present on all cell types. Fe^2+^ is rapidly oxidized to Fe^3+^ once outside the cell by ferroxidases such as hephaestin or ceruloplasmin (expressed on astrocytes mainly). Amyloid precursor protein (APP) is expressed on neurons, astrocytes and microglia, and has been found to facilitate iron export in neurons by stabilizing ferroportin ([@B115]). **(B)** Injury to the brain/neurovascular unit causes BBB damage, microglia activation, astrogliosis, and eventually damage to neurons and the myelin sheath surrounding axons. Dysregulation of iron metabolism in the brain following TBI can result in the accumulation of redox-active ferrous iron in various brain cells. This is possibly due to alterations in the expression/function of regulatory proteins such as ferroportin, ferritin and ceruloplasmin, which fail to export iron from cells and thereby increases the labile iron pool. Iron accumulation in microgia can cause increased pro-inflammatory cytokine production, and vice versa ([@B104]). Taken together, iron accumulation in the brain can promote oxidative stress that contributes to neurodegeneration.](fnins-12-00981-g002){#F2}

Since iron is a transition metal, Fe^2+^ and Fe^3+^ can react with hydrogen peroxide and oxygen, respectively, catalyzing hydroxyl and superoxide radicals and can also react with lipids leading to the formation of alkoxy and peroxy radicals ([@B39]). This is known as the Haber-Weiss and Fenton reaction. Hence, iron can increase ROS by participating in redox reactions and in turn lead to cellular oxidative stress and eventually cell death ([@B55]). Sufficient iron storage in the brain either by ferritin, neuromelanin (mainly in substantia nigra neurons) or hemosiderin is essential to prevent oxidative damage ([@B4]).

Deficiency of iron or excessive iron, or changes in iron-regulating protein expression, can therefore be catastrophic to cells/tissues and are known to contribute to numerous disorders such as anemia, aceruloplasminemia, neuroferritinopathy, mitochondrial membrane protein-associated neurodegeneration (MPAN) and pantothenate kinase-associated neurodegeneration (PKAN) ([@B62]; [@B48]). Patients with inherited conditions that develop increased brain iron accumulation present with cognitive, motor and neuropsychiatric decline ([@B94]; [@B48]). Excessive iron accumulation is harmful because it can promote the formation of free radicals resulting in oxidative stress, lipid peroxidation, protein aggregation and eventually cell/neuronal death ([@B77]). On the other hand, iron deficiency can result in impaired myelin generation, neurotransmission and enzymatic processing. Iron deficiency anemia has been linked to the development of AD, and individuals with anemia are twice as likely to develop mild cognitive impairments over time ([@B30]). A recent study consisting of 939 patients with TBI found that anemia (i.e., presenting with low hemoglobin levels and low plasma iron), which affects approximately half of hospitalized TBI patients, is associated with poor outcomes following TBI ([@B65]). Taken together this shows that a delicate balance of iron metabolism needs to be achieved to protect the brain against its potentially harmful effects, in both healthy and diseased states.

Iron in Neurodegenerative Diseases
==================================

Iron dyshomeostasis appears to be a central factor in neurodegenerative conditions such as AD, PD, ALS, Huntington's disease, and Friedreich's ataxia ([@B80]; [@B2]). For decades, deposits of iron have been detected in brain lesions of patients with these neurodegenerative conditions ([@B40]; [@B11]; [@B1]). How iron accumulates in the diseased/injured brain is not known, however, heme-bound iron that is derived from the circulation and non-heme bound iron (i.e., all iron not bound to heme protein) are both present in affected tissue ([@B76]; [@B111]). It is likely that the deposition of iron into the brain parenchyma in these conditions is the result of either hemorrhage/microbleeds (i.e., heme-bound iron), damaged cells (i.e., neurons, oligodendrocytes and microglia), and myelin, inflammatory processes, degradation of erythrocytes and heme proteins, and/or dysregulation of important iron-related proteins (e.g., ceruloplasmin, ferroportin) ([@B42]; [@B43]; [@B76]). Excessive iron that is localized in affected neurons and glia can be found in brain regions such as the substantia nigra (dopaminergic neurons) in PD ([@B11]), and can also accompany regions of amyloid plaques and neurofibrillary tangles in AD ([@B95]). Similarly, patients with MS present with increased iron deposition in deep gray matter regions correlating with poor integrity of the white matter tissue ([@B12]). Increased brain iron accumulation in these neurological conditions have correlated with poorer functional outcomes and disease severity in patients ([@B124]; [@B106]).

Although it is not yet clear whether iron is a causative or a contributing factor, its presence drives redox reactions, inflammatory processes as well as mitochondrial dysfunction ([@B104]). Iron accumulation in dopaminergic neurons, which are typically affected in PD, can exacerbate α-synuclein pathology and induce autophagy dysfunction ([@B110]). Ferric iron (Fe^3+^) can cause the formation of neurofibrillary tangles by binding to aggregated hyperphosphorylated tau proteins and can also become reduced to its destructive redox-active form (free Fe^2+^) during the process ([@B119]; [@B80]). Iron can promote the toxicity of amyloid beta (Aß) by affecting aggregation, oligomerization, and amyloidosis of the peptide ([@B66]). It is also likely that the pathogenicity of Aß (e.g., in AD) is at least in part due to its interaction with iron and the potentiation of redox reactions ([@B90]). In addition, expression of proteins that are involved in the regulation of iron are altered in these disease states; ceruloplasmin, ferroportin, and furin (regulates hepcidin) are decreased while DMT1 (iron importer) and transferrin are increased ([@B43]; [@B111]; [@B84]). The main iron storage protein in the brain, ferritin, is elevated in the cerebrospinal fluid (CSF) of patients with AD as well as areas containing amyloid plaques, and this protein also increases with age ([@B52]; [@B122]; [@B7]). These regulatory proteins in addition to iron are also associated with the production of Aß and hyperphosphorylated tau ([@B89]). Together this reveals that the failure lies with various crucial proteins involved in the regulation of iron and is a possible explanation for the accumulation of iron in the brain.

Overall, increased iron accumulation in the brain, over and above the age-related changes, may be an indirect indicator of the progression and severity of AD and PD, and possibly other neurological conditions ([@B106]; [@B1]). Elevated brain iron as measured by quantitative susceptibility mapping (via MRI) and increased CSF ferritin levels observed in patients with AD and mild cognitive impairment, were found to be predictive of cognitive decline over the long-term, and correlated with amyloid-β pathology ([@B9]) and apolipoprotein E genotype ([@B8]), respectively. Considering that brain iron content increases with age and that age is a major risk factor associated with neurodegenerative disease, the detection of iron using non-invasive imaging techniques may therefore prove to be a useful diagnostic tool as an early indicator of disease onset.

Interplay of Iron, Inflammation and Neurodegeneration
=====================================================

The immune system similarly plays an important role in the pathogenesis of neurodegenerative diseases although its interaction with biometals is unappreciated. Immune cells are also equipped with transferrin and ferroportin receptors to enable the influx/efflux of iron to meet their cellular needs. In particular, phagocytic immune cells such as microglia (brain-specific macrophages) have an important role in the regulation and distribution of iron since they function to engulf and recycle damaged/dying cells and thereby release iron into the brain interstitial space ([@B75]; [@B3]). Intracellular iron accumulation is associated with macrophage infiltration/polarization and increased TNF-α expression ([@B59]). Indeed, inflammatory cytokines (mainly IL-6 and TNF-α) and mediators such as LPS induce the expression of iron transporter receptors (e.g., DMT-1) and promote an increase in the accumulation of iron in neurons and microglia ([@B104]).

Iron can accumulate in myeloid cells including microglia and monocytes, causing oxidative damage to the cell and promoting chronic neuroinflammation. This is a typical feature observed in several neurological conditions including MS and AD ([@B3]; [@B100]). *In vitro* studies reveal that iron can directly increase NFκB activity and stimulate pro-inflammatory cytokine production in microglia ([@B91]). Indeed, hemosiderin-laden macrophages were present in the frontal and temporal lobes of a patient with mild TBI ([@B14]). Damaged oligodendrocytes and myelin in neuroinflammatory conditions including MS were determined as the main sources of extracellular iron in the brain parenchyma ([@B42]).

This interplay of iron deposition with phagocytic cells (macrophages) can lead to neuronal damage not only due to oxidative stress and free radical formation but also through the promotion of pro-inflammatory mediators that further contributes to secondary damage in TBI. There is also the hypothesis that the inflammatory cells that migrate to the site of injury in TBI (or plaque regions in neurodegenerative diseases) are largely responsible for depositing iron ([@B92]; [@B3]). Hence, an unrecognized link between iron accumulation and the involvement of the immune response in TBI warrants investigation considering both these processes are persistently active in the brain from weeks to months following injury. Whether iron dyshomeostasis in the brain is the process that promotes glial reactivity and drives neuroinflammatory responses, or vice versa, is unknown. Perhaps both these processes are simultaneously contributing to brain damage and consequential neurological impairment following TBI. Supporting this, a recent review proposed a positive feedback cycle in which mitochondrial dysfunction, inflammation, and iron accumulation are critical synergistic mechanisms that induce and enhance one another, and eventually become responsible for neuronal/cell death in the pathogenesis of neurodegenerative diseases ([@B77]; [@B104]).

The Role of Iron in TBI
=======================

Iron deposits that accumulate in the brain can consist of both non-heme and heme iron sub-types. These features are more commonly observed in neurodegenerative conditions such as AD, although increasing evidence suggests that both these subtypes of iron are increased in the injured brain after TBI ([@B76]). Heme-bound iron is commonly found coinciding with intracranial hemorrhage, along with deposition of hemosiderin and ferritin due to the phagocytosis of erythrocytes by microglia/macrophages ([@B58]; [@B76]).

A feature seen in TBI as well as several neurodegenerative diseases is the formation of cerebral microhemorrhages. These have been observed at both the acute and chronic stages of TBI, in experimental models of single and repetitive TBI ([@B26]; [@B35]) as well as in a subgroup of mild TBI patients ([@B83]; [@B45]; [@B76]). The clinical relevance of cerebral microhemorrhages on TBI outcome is not yet clear ([@B93]; [@B51]; [@B105]) although the presence of microhemorrhages following TBI is a suggested predictor of injury severity ([@B50]; [@B61]). Microbleeds have been negatively associated with cognitive outcomes in patients with mild cognitive impairment, stroke and MS ([@B112]; [@B127]; [@B64]). Microhemorrhages are interestingly associated with areas of white matter damage, BBB breakdown, demyelination, and inflammation in experimental TBI ([@B35]). Microbleeds, which can be detected by Prussian blue iron staining, reveal an abnormal accumulation of iron and ferritin/hemosiderin that have been found to be toxic to brain-specific cells (neurons, astrocytes, and microglia) and endothelial cells ([@B35]). More importantly, non-heme bound iron and free iron are also elevated in the brain following TBI and are considered more problematic ([@B76]), as shown in Figure [2](#F2){ref-type="fig"}.

The origin of brain iron deposits independent of heme-bound iron in TBI is not yet known although several hypotheses exist. Dysregulation of ceruloplasmin (e.g., decreased levels) can lead to an increase in free copper ions and a concomitant decrease in ferroxidase activity, thereby reducing clearance of iron from the CNS (i.e., increasing iron deposition). Ceruloplasmin deficient mice subjected to TBI showed elevated brain iron levels and exacerbated infarct volume ([@B10]). TBI (and specifically intracerebral hemorrhage: ICH) often accompanies hemorrhage, increased vascularisation and BBB breakdown, which likely results in heme-bound iron deposition in the brain initially. In this instance, the enzyme heme-oxygenase 1 (HO-1) is involved in the degradation of heme-bound iron into free iron or non-heme bound iron ([@B13]). HO-1 is also suggested to be involved in induction of antioxidants bilirubin and biliverdin, and can therefore protect against oxidative stress. Indeed, HO-1 expression is heightened following TBI in both experimental models ([@B31]; [@B78]) and in humans over a long-term period ([@B13]). HO-1 is likely protective at the acute stage through its antioxidant properties and clearance of heme-bound iron but it also could be responsible for non-heme bound iron accumulation in the brain, thereby increasing labile iron content over time. Free iron released from the degradation of heme proteins is a main source of oxidative stress, particularly in the injured brain ([@B19]). Excessive quantities of labile iron (Figure [2](#F2){ref-type="fig"}) can be harmful by inducing excitotoxic-related neuronal death, impaired neurotransmission, and mitochondrial dysfunction ([@B77]; [@B104]; [@B111]).

Literature characterizing the metal profile and spatiotemporal distribution of iron is relatively sparse in TBI of varying injury severities and repetitive injuries, as well as ICH and stroke, in both clinical (see Table [1](#T1){ref-type="table"}) and animal studies (see Table [2](#T2){ref-type="table"}). Importantly, the consequence of iron accumulation in the brain following TBI is currently unknown, although it is associated with the development of post-traumatic epilepsy ([@B113]; [@B114]; [@B103]). Brain-region specific accumulation of iron has been documented in patients with mild TBI, via magnetic resonance imaging (MRI) approaches such as Magnetic field correlation (MFC) and susceptibility weighted imaging (SWI) ([@B88]; [@B76]; [@B70]). Various regions of the brain are affected including the hippocampus, globus pallidus, thalamus, substantia nigra, and corpus callosum, as summarized in Table [1](#T1){ref-type="table"}. Non-heme iron is more sensitively detected by MR imaging techniques although limitations do exist (e.g., tissue fluid content can affect iron quantitation) ([@B88]). However, it can be concluded that non-heme bound iron accumulates in deep gray matter areas of the brain and may contribute to pathological secondary injury (e.g., oxidative stress) following TBI since abnormal iron deposition correlated with poor cognitive outcome ([@B88]; [@B70]).

###### 

Brain iron accumulation in brain injury; evidence from clinical studies.

  Brain injury               Patients                                                              Detection method                  Iron deposits/ region                                                                                                                      Associated pathology                                                       Outcome/prognosis                                                                                                        Study
  -------------------------- --------------------------------------------------------------------- --------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------ ---------
  Stroke                     Ischemic stroke (*n* = 77) and transient ischemic attack (*n* = 74)   SWI                               Lenticular nucleus                                                                                                                         Correlated with cerebral microbleeds                                       N/A                                                                                                                      [@B68]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
                             Unilateral ischemic stroke (*n* = 36)                                 T2-MRI                            Thalamus                                                                                                                                   N/A                                                                        N/A                                                                                                                      [@B107]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
                             Ischemic stroke patients (*n* = 172)                                  R2 mapping, MRI                   Thalamus, ipsilateral to infarct location                                                                                                  N/A                                                                        Associated with poor functional and cognitive outcome, and depression/anxiety at 1 year                                  [@B60]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  ICH                        Spontaneous ICH patients (*n* = 2, case study)                        T2-MRI                            Perihematoma, basal ganglia region (at 7 days)                                                                                             N/A                                                                        N/A                                                                                                                      [@B20]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  TBI                        Mild TBI patients (*n* = 39)                                          SWI                               Caudate nucleus, lenticular nucleus, hippocampus, thalamus, right substantia nigra, red nucleus, and the splenium of the corpus callosum   N/A                                                                        Negative correlation with Mini-Mental State Examination (MMSE) scores in mild TBI group compared to controls             [@B70]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
                             Mild TBI patients (*n* = 28)                                          MRI mapping/ MFC                  Globus pallidus and thalamus                                                                                                               N/A                                                                        High MFC values (suggesting iron deposits) inversely correlated with cognitive function (i.e., Stroop color word test)   [@B88]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
                             TBI patients (*n* = 19)                                               PCR and IHC                       Peri-contusional cortex (12 and 48 h post-injury)                                                                                          Increased ferritin H-chain expression in neurons and iron in glial cells   N/A                                                                                                                      [@B67]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Repetitive mild TBI/ CTE   CTE (Dementia Pugilistica)                                            Laser micro-probe mass analysis   Temporal cortex                                                                                                                            Iron deposits in neuronal neurofibrillary tangles                          More prominent in Dementia Pugilistica than AD                                                                           [@B15]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

CTE, chronic traumatic encephalopathy; IHC, immunohistochemistry; ICH, intracerebral hemorrhage; MRI, magnetic resonance imaging; MFC, magnetic field correlation; MMSE, Mini-Mental State Examination; N/A, not available; PCR, polymerase chain reaction; SWI, susceptibility weighted imaging.

###### 

Brain iron accumulation in brain injury; evidence from experimental studies.

  Brain injury          Model                                                                Iron deposits/ region                                                                                  Time-period                  Associated pathology                                                Outcome/ prognosis                                                                                                                                                        Study
  --------------------- -------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------ ---------------------------- ------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------
  Stroke                Rat, middle cerebral artery occlusion (MCAO)                         Thalamus; increased iron in microglia (at 3 wks), parenchyma (at 7 wks) and APP deposits (at 24 wks)   Over 24 weeks post-injury    Neuronal loss, increased microglia activation and HO-1 expression   Behavioral deficits up to 24 wks                                                                                                                                          [@B53]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
                        Rat, permanent photo-thrombotic cortical vessel occlusion            Free (labile) iron and total iron increased in the ischemic lesion                                     1 h post-injury              N/A                                                                 Iron chelator 2,2'-dipyridyl (Bipyridine), injected 15 min or 1 h post-injury, improved BBB integrity                                                                     [@B74]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  ICH                   Rat, ICH model -- collagenase                                        Non-heme and total iron in injured striatum                                                            3 days and 4 wks post-ICH    Increased lesion volume                                             N/A                                                                                                                                                                       [@B6]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
                        Mice, ICH model -- collagenase VII-S injected in the left striatum   Peri-hematomal region                                                                                  Peaking at 3 days post-ICH   Increased lesion volume and neuronal degeneration                   Neurological deficits up to 28 days. Iron chelator VK-28 reduced brain oedema, ROS and white matter injury yet promoted M2-microglia polarization and improved outcomes   [@B63]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
                        Rat, ICH, autologous whole blood injected into basal ganglia         Increased brain non-heme iron, transferrin/transferrin receptor and HO-1 levels                        Over 4 weeks                 N/A                                                                 N/A                                                                                                                                                                       [@B116]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  TBI                   Mice, CCI model                                                      Ipsilateral parietal cortex (LA-ICPMS)                                                                 3--28 days post-CCI          N/A                                                                 N/A                                                                                                                                                                       [@B85]; [@B86]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
                        Mice, CCI model                                                      Thalamus and internal capsule (T2-MRI)                                                                 1 and 2 months post-CCI      Reactive astrocytes and microglia                                   N/A                                                                                                                                                                       [@B79]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Repetitive mild TBI   Rat, mild CCI (2 impacts; 1, 3 or 7 days apart)                      Extravascular iron deposits at lesion site (IHC)                                                       14 days                      Correlated with lesion volume and reactive glial cells              Behavioral and memory deficits at 1 month post-injury                                                                                                                     [@B49]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

APP, amyloid precursor protein; HO-1, heme oxygenase-1; LA-ICPMS, laser ablation-inductively coupled plasma-mass spectrometry; MRI, magnetic resonance imaging; MCAO, middle cerebral artery occlusion.

Recent studies ([@B85], [@B86]) thoroughly analyzed the time-dependent alteration in metals including iron, zinc, and copper, in the brain by laser ablation-inductively coupled plasma-mass spectrometry (LA-ICPMS) in a mouse controlled cortical impact (CCI) model. Elevated iron concentrations were detected at the impact site as early as 3 days and were persistently elevated up to 28 days in both young ([@B85]) and aged mice ([@B86]) following injury. Supporting this, histological staining revealed intracellular iron accumulated in the cortex and hippocampal regions of the injured hemisphere ([@B85]). Another study subjected aged mice (21--24 month old) to the CCI model and found increased iron deposition using T2-weighted MRI in the ipsilateral thalamus that accompanied astrogliosis and microgliosis at 1 and 2 months post-TBI ([@B79]). The authors suggest that free iron may be elevated as a result of degenerating thalamic neurons ([@B79]). Therefore, the continued presence of both inflammation and iron accumulation in the lesion likely contributes to ongoing pathology following TBI, as summarized in Figures [1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"}.

Iron in Aging, Injury and Neurodegeneration
===========================================

It is well recognized that iron as well as iron-related proteins (e.g., ferritin and HO-1) progressively increase in the aging brain ([@B47]; [@B98]). Microglia and astrocytes, but not oligodendrocytes, appear to accumulate iron more with age ([@B122]; [@B4]). Regions of the brain typically affected by age-related iron accumulation are the hippocampus, cortex, cerebellum, and most prominently the basal ganglia. Interestingly, these regions are commonly linked to neurodegenerative diseases ([@B4]). Indeed, age remains one of the greatest risk factors associated with poor outcomes following TBI, and the development of neurodegenerative/neuroinflammatory conditions ([@B99]; [@B111]). In aged individuals, iron accumulation in the brain could be caused by events that coincide with the aging process including increased permeability of the BBB, inflammation, dysregulation of iron-related proteins, mitochondrial dysfunction, and altered iron distribution within the CNS ([@B29]; [@B111]). Therefore, it is not clear whether age-related iron accumulation causes, or is rather a consequence of, neurodegeneration that commonly occurs with aging. Importantly, iron deposition in the aged brain has been linked to cognitive and motor deficits in the elderly ([@B87]), and motor dysfunction in rhesus monkeys ([@B18]). Since aged individuals generally exhibit co-morbidities and present with systemic inflammation and altered neurovascular unit integrity among other age-related pathological processes ([@B99]), this renders the brain vulnerable to iron-mediated oxidative damage ([@B98]). This can be particularly problematic for an already compromised brain following TBI. The extent of iron deposition between adults and elderly TBI patients has not yet been directly examined clinically. However, a recent study showed that aged (24 month old) mice have higher levels of iron (as well as other metals) in both the injured and contralateral (uninjured) hemisphere following TBI compared to young (3 month old) mice ([@B86]). This heightened increase in brain iron levels can potentiate oxidative stress and neurotoxicity (as extensively covered in this review), and therefore is a possible explanation for the cognitive decline and overall worse outcomes observed in the aging TBI population. Further research is needed to better understand the role of iron in aging and its link to TBI and neurodegenerative disease.

Therapeutic Relevance and Future Directions
===========================================

Iron-mediated brain damage occurs in patients with TBI over a chronic time-period, and it is speculated that increasing iron deposition (with age) can predispose these individuals to the development of neurodegenerative diseases later in life or to post-traumatic epilepsy (see Figure [1](#F1){ref-type="fig"}). Hence, a targeted therapeutic approach to regulate iron levels in TBI patients will be an important advancement in limiting progressive neurodegeneration and neurological deficits that accompanies TBI of varying severities, and thereby reduce the risk of neurological disorders. Iron chelation therapies work by binding free iron and removing excess iron from the blood. Iron chelation not only works by scavenging labile free iron but some can also act as an antioxidant that neutralizes the radical reaction by donating hydrogen (e.g., deferiprone, HBED iron chelator) ([@B56]). They can also bind/remove other metals yet have a higher affinity for iron, and the absorption and tissue penetration properties of the different iron chelators can vary (e.g., desferrioxamine is poorly absorbed in the gut while deferiprone and deferasirox are orally active) thereby different routes of administration are needed ([@B54]; [@B28]). Iron chelation therapy has only been investigated in a few pilot clinical trials of common neurological conditions including AD ([@B22]), PD ([@B24]; [@B73]), and MS ([@B71]). As yet, no compelling evidence has come to light with the use of iron chelators in these conditions, although they have proved relatively effective in attenuating disease progression in PD. The brain permeable iron chelator, deferiprone, decreased iron deposits in the substantia nigra, and slowed disease-severity progression in a small-scale study involving PD patients (*n* = 40) ([@B24]). However, another pilot clinical trial assessing deferiprone in PD patients only found a trending improvement in motor function over 6 months ([@B73]); hence more extensive clinical and experimental studies are warranted. Baicalin and deferoxamine, which are iron chelating drugs that can (baicalin) or cannot (deferoxamine) pass through the BBB, were assessed in a rat model of PD. Both these treatments inhibited iron deposition in the substantia nigra as well as the striatum, dentate gyrus, dentate-interpositus, and cerebellum, protected dopaminergic neurons from death ([@B118]).

This strategy of chelating iron has yet to be trialed in patients with TBI, or chronic traumatic encephalopathy (CTE) patients with repetitive head injury, nor has it been greatly explored in animal models of TBI. However, it remains a potential treatment option based on the few promising experimental TBI studies that have assessed the effect of iron chelators (i.e., deferoxamine or dextran-coupled deferoxamine) in experimental models that will be described hereafter.

Iron Chelation in TBI
=====================

Only a handful of studies to date have investigated the therapeutic potential of chelating iron in experimental TBI models, mainly via the ferric iron chelator deferoxamine, as summarized in Table [3](#T3){ref-type="table"}. However, deferoxamine has several limitations including its inability to cross the BBB, rapid elimination rate and it can theoretically generate superoxide radicals through binding Fe^3+^ leading to Fe^2+^ oxidation ([@B57]; [@B41]).

###### 

The effectiveness of iron chelators in experimental TBI models.

  Severity              Model                                             Iron chelator                                                                          Effect of treatment                                                                                                                 Time-frame (post-injury)   Protective?                                   Study
  --------------------- ------------------------------------------------- -------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------- -------------------------- --------------------------------------------- ---------
  Mild TBI              Mice, CCI model                                   HBED (N,N′-Di(2-hydroxybenzyl) ethylenediamine-N,N′-diacetic acid monohydrochloride)   Improved motor function and neurological deficits. Reduction in cortical injury volume, microgliosis and oxidative stress markers   3 days                     Yes                                           [@B56]
  Moderate TBI          Rats, CCI model                                   Deferoxamine                                                                           Improved spatial memory (Morris water maze) but no change in cortical tissue loss between deferoxamine and vehicle control          Up to 17 days              Yes, but only in spatial memory performance   [@B69]
  Moderate-severe TBI   Rats, fluid percussion injury model               Deferoxamine                                                                           Reduced hydrocephalus development after TBI and decreased heme oxygenase-1 expression                                               24 h                       No outcome measures tested                    [@B126]
  Severe TBI            Rats, weight drop model                           Deferoxamine                                                                           Improved Morris water maze performance (spatial memory) and reduced brain atrophy                                                   28 days                    Yes                                           [@B125]
                        Mice, weight drop model (loss of consciousness)   Dextran-coupled deferoxamine                                                           Improved grip-strength compared to mice treated with deferoxamine or dextran alone                                                  1 h                        Yes                                           [@B81]
                                                                                                                                                                                                                                                                                                                                                                              

In a recent study, the brain permeable iron chelator HBED was assessed in its effectiveness to attenuate iron-mediated brain damage in a mouse model of TBI (i.e., CCI) ([@B56]). They found that HBED improved locomotor function along with a reduction in lesion volumes and hippocampal swelling. Interestingly, HBED also limited microgliosis and the expression of immune markers in the corpus callosum ([@B56]). This pointed to a potential mechanism through which the drug mediates its protective effects. However, a limitation of this study is that HBED treatment did not significantly reduce iron in the brain as measured by Perls' staining ([@B56]). On the other hand, deferoxamine treatment reduced the levels of iron and iron-storage proteins (ferritin and transferrin) in the brain, which were elevated at 28 days post-TBI in rats. This was accompanied by a reduction in brain atrophy in the injured rats treated with deferoxamine as well as an improvement in spatial memory and learning, at 28 days after TBI ([@B125]). A similar protective effect with deferoxamine treatment was also observed in earlier studies at an acute period following TBI ([@B81]; [@B69]).

Several key limitations of these studies exist, including the short period of treatment, limited outcome measures and only one recent study assessed brain pathology at one time-point. Hence, there is a great need for long-term sequential analysis for the use of iron chelators (specifically those that are brain-permeable) in experimental TBI models, in which the influence of iron chelation on functional outcomes, pathology (e.g., oxidative stress, cell death, BBB breakdown), other biochemical alterations and also inflammation are essential before moving into clinical trials.

However, iron chelation therapy has been more thoroughly explored as a strategy for combating brain iron overload in ICH and to some degree in stroke (See Table [2](#T2){ref-type="table"}), although these are still in the preclinical phase with only a few currently active clinical trials ([@B120]; [@B121]; [@B123]). In particular, a small-scale clinical trial using deferoxamine in ICH patients (*n* = 21) showed improvement in oedema volume and hematoma absorption over a period of 30 days ([@B121]). Deferoxamine reduces odema, cell death, hippocampal degeneration and also inflammation following experimental ICH ([@B34]). Neuronal death and behavioral deficits were attenuated by deferoxamine treatment in aged rats with induced ICH ([@B46]). Deferiprone treatment has shown promise in reversing iron toxicity in the brain and improving outcome. Treatment was remarkably effective when deferiprone was combined with the antioxidant n-acetyl cysteine, in rats fed with a high iron-supplemented diet ([@B96], [@B97]). This combined treatment had a greater efficacy in improving learning and memory, long-term potentiation, mitochondrial function, BBB integrity and cell death, compared to individual treatment in iron-overloaded rats ([@B96], [@B97]). In addition, brain-related pathology including Aβ deposition, tau-hyperphosphorylation and dendritic spine loss were all significantly reduced to a greater extent with combined treatment ([@B97]).

Most recently, the use of a ferroptosis (a form of iron-dependent cell death) inhibitor was shown to reduce iron deposition and result in a host of downstream benefits, including decreased neuronal degeneration and improved behavioral outcomes (motor and cognitive function) ([@B117]). Thus, ferroptosis may represent a new pathway of relevance for TBI, and such studies are currently underway in our lab.

Conclusion
==========

Brain iron accumulation is a common feature of most neurodegenerative/neurological conditions including TBI. It is increasingly becoming clear that iron plays a detrimental role in the pathogenesis of various neurodegenerative diseases, however, its relationship to TBI pathobiology still requires consolidation. Although iron chelation with deferoxamine has shown limited potential in experimental TBI models, using a chelator that can penetrate the BBB (e.g., deferiprone, HBED, VK-28), with a known ability to lessen iron-induced neurotoxicity in ICH and neurodegenerative diseases, could prove to be superior than previously tested iron chelators in improving outcome after TBI. Whether a specified time-window for treatment is required (e.g., immediate vs delayed treatment) also needs to be addressed (as does the notion that a combination of iron and zinc-targeted treatments may have a synergistic benefit in TBI). Targeting both iron accumulation and subsequent oxidative damage and/or inflammation by proposed combined therapy (e.g., other antioxidants or anti-inflammatory agents) has not yet been assessed preclinically in TBI ([@B41]). This approach has the potential of limiting acute secondary injury and protecting against neurological deterioration, as well as attenuating long-term neurodegeneration thereby reducing the risk of neurodegenerative disease development. Lastly, there is a great need for experimental studies to focus on the long-term consequences of iron-mediated damage considering iron deposition progresses over time; as seen with age, neurodegenerative diseases as well as TBI.
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